Joseph C Papa
CIK 1242215 · President and CEO · last filed 2026-10-02
Joseph C Papa is a President and CEO who has filed 108 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for CADL, was dated Oct 2, 2026. Across all open-market trades the lifetime net is −$40.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $23.0M across reported positions. 24 SEC filings were submitted jointly with Bausch Health Companies Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PRGO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
300 PROFESSIONAL DRIVE
GAITHERSBURG, MD 20879
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CADL | Director | 102,271 | $7.79 | $796.7K | $73.1K | 10 | 2026-10-02 |
| MIST | Director | 100,000 | $0.64 | $64.4K | $0 | 4 | 2026-06-12 |
| EBS | President and CEO | 493,153 | $6.34 | $3.13M | $349.8K | 6 | 2026-05-01 |
| Prometheus Biosciences, Inc. (RXDX) Delisted | Director | 0 | $199.92 | $0 | $285.0K | 6 | 2023-06-16 |
| BHC | CHAIRMAN & CEO | 1,395,371 | $6.35 | $8.86M | $2.08M | 18 | 2022-05-12 |
| BLCO | CEO & Chairman | 472,222 | $17.58 | $8.30M | $0 | 1 | 2022-05-09 |
| PRGO | CEO | 118,515 | $15.82 | $1.87M | -$43.21M | 58 | 2016-03-01 |
Recent Filings
108 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-02 | CADL | Grant (A) | — | $0 | EDGAR |
| 2026-07-01 | CADL | Grant (A) | — | $0 | EDGAR |
| 2026-06-24 | CADL | Grant (A) | — | $0 | EDGAR |
| 2026-06-12 | MIST | Grant (A) | — | $0 | EDGAR |
| 2026-05-01 | EBS | Grant (A) | +187,708 | $0 | EDGAR |
| 2026-04-02 | CADL | Grant (A) | — | $0 | EDGAR |
| 2026-03-05 | EBS | Mixed | −37,055 | -$312.7K | EDGAR |
| 2025-07-15 | MIST | Grant (A) | +100,000 | $0 | EDGAR |
| 2025-06-26 | CADL | Grant (A) | +64,239 | $300.0K | EDGAR |
| 2025-06-18 | CADL | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.